| Fiscal Period | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Period End Date | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
| Total Liabilities Shareholders' Equity | 4,108.07 | 3,556.62 | 3,326.58 | 4,633.28 |
| Accumulated Depreciation Total | -295.62 | -283.13 | -255.54 | -222.66 |
| Cash Equivalents | 435.00 | 0.00 | 0.04 | 230.06 |
| Other Liabilities Total | 249.11 | 247.56 | 255.49 | 264.27 |
| Accrued Expenses | 155.98 | 114.21 | 94.71 | 103.08 |
| Long Term Debt | 0.00 | - | - | - |
| Common Stock Total | 169.41 | 169.41 | 169.41 | 169.41 |
| Other Current Assets Total | 26.39 | 23.93 | 23.29 | 23.37 |
| Prepaid Expenses | 18.89 | 20.62 | 14.96 | 13.93 |
| Total Assets | 4,108.07 | 3,556.62 | 3,326.58 | 4,633.28 |
| Current Portof LT Debt/ Capital Leases | 7.46 | 12.20 | 12.08 | 12.45 |
| Cash | 103.85 | 64.17 | 34.90 | 56.13 |
| Total Equity | 1,951.31 | 1,777.64 | 1,741.27 | 2,662.96 |
| Long Term Investments | 0.81 | 0.94 | 1.09 | 1.21 |
| Retained Earnings( Accumulated Deficit) | 1,781.90 | 1,608.23 | 1,571.87 | 2,493.55 |
| Total Common Shares Outstanding | 16.94 | 16.94 | 16.94 | 16.94 |
| Property/ Plant/ Equipment Total- Gross | 579.48 | 593.86 | 570.66 | 548.10 |
| Tangible Book Valueper Share Common Eq | 114.40 | 103.54 | 100.77 | 155.16 |
| Total Liabilities | 2,156.75 | 1,778.98 | 1,585.31 | 1,970.32 |
| Total Debt | 9.95 | 18.67 | 15.54 | 20.08 |
| Short Term Investments | 1,959.26 | 1,792.65 | 1,619.18 | 2,544.69 |
| Cashand Short Term Investments | 2,498.10 | 1,856.82 | 1,654.12 | 2,830.88 |
| Total Receivables Net | 384.77 | 371.99 | 341.93 | 305.17 |
| Notes Payable/ Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Accounts Receivable- Trade Net | 301.50 | 231.07 | 206.45 | 212.88 |
| Property/ Plant/ Equipment Total- Net | 283.86 | 310.73 | 315.12 | 325.45 |
| Total Current Liabilities | 1,905.15 | 1,524.95 | 1,326.37 | 1,698.43 |
| Total Inventory | 481.74 | 525.05 | 459.97 | 534.70 |
| Accounts Payable | 708.25 | 625.41 | 427.79 | 570.55 |
| Other Currentliabilities Total | 1,033.47 | 773.13 | 791.79 | 1,012.35 |
| Total Long Term Debt | 2.49 | 6.47 | 3.46 | 7.62 |
| Intangibles Net | 13.33 | 23.55 | 34.09 | 34.50 |
| Other Long Term Assets Total | 185.68 | 191.70 | 179.84 | 157.02 |
| Note Receivable- Long Term | 214.50 | 231.27 | 302.18 | 407.07 |
| period Length | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 3,409.88 | 2,798.42 | 2,494.26 | 3,708.03 |
| Capital Lease Obligations | 2.49 | 6.47 | 3.46 | 7.62 |
GlaxoSmithKline Pharmaceuticals Dividend GlaxoSmithKline Pharmaceuticals Bonus GlaxoSmithKline Pharmaceuticals News GlaxoSmithKline Pharmaceuticals AGM GlaxoSmithKline Pharmaceuticals Rights GlaxoSmithKline Pharmaceuticals Splits GlaxoSmithKline Pharmaceuticals Board Meetings GlaxoSmithKline Pharmaceuticals Key Metrics GlaxoSmithKline Pharmaceuticals Shareholdings GlaxoSmithKline Pharmaceuticals Profit Loss GlaxoSmithKline Pharmaceuticals Cashflow GlaxoSmithKline Pharmaceuticals Q1 Results GlaxoSmithKline Pharmaceuticals Q2 Results GlaxoSmithKline Pharmaceuticals Q3 Results GlaxoSmithKline Pharmaceuticals Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks